BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26015309)

  • 1. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
    Emarh M
    Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
    Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
    Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia.
    Uysal G; Acmaz G; Madendag Y; Cagli F; Akkaya H; Madendag I; Karakilic EU
    Gynecol Obstet Invest; 2018; 83(2):151-155. PubMed ID: 28715800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-Releasing Hormone Analog Combined with Depot Medroxyprogesterone Acetate in the Management of Endometrial Hyperplasia A Prospective Randomized Clinical Study.
    Demir Karakilic I; Karabacak O; Karabacak N; Guler I; Korucuoglu U
    J Reprod Med; 2016 Aug; 61(7-8):361-367. PubMed ID: 30408383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for complex atypical hyperplasia of the endometrium.
    Jobo T; Kawaguchi M; Imai M; Kuramoto H
    Eur J Gynaecol Oncol; 2001; 22(5):365-8. PubMed ID: 11766742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.
    Nooh AM; Abdeldayem HM; Girbash EF; Arafa EM; Atwa K; Abdel-Raouf SM
    Reprod Sci; 2016 Apr; 23(4):448-54. PubMed ID: 26718306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the effects and safety of dydrogesterone and medroxyprogesterone acetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study].
    Lou YC; Zhou S; Liao JB; Shao WY; Hu YY; Ning CC; Wang Q; Gulinazi Y; Yang BY; Cheng YL; Wu PF; Zhu Q; Zhou XR; Shan WW; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Jul; 58(7):526-535. PubMed ID: 37474326
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.
    Ozdegirmenci O; Kayikcioglu F; Bozkurt U; Akgul MA; Haberal A
    Gynecol Obstet Invest; 2011; 72(1):10-4. PubMed ID: 21266792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
    Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
    J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
    Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
    J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
    Ismail MT; Fahmy DM; Elshmaa NS
    Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
    Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
    Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
    Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
    BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
    J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.